Linda R Duska

14PUBLICATIONS
93CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modellingMolecular targetsPreventative health carePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 12, 2025
The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

Linda R Duska, Jonathan Lim, Tirza Areli Calderón Boyle

|Feb 08, 2025
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.

Linda R Duska, Gina R Petroni, Premal H Thaker

|Jan 21, 2025
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).

Husam A Alqaisi, David E Cohn, Jing-Yi Chern

|Oct 22, 2024
Real-world perioperative treatment patterns and burden of recurrent disease in patients with high-risk endometrial cancer: a SEER-Medicare study.

Vimalanand S Prabhu, Kalé Kponee-Shovein, Mu Cheng

|Oct 03, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.

Jung-Min Lee, Mark F Brady, Austin Miller

|Jun 04, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.

Patricia J Keller, Elizabeth J Adams, Rentian Wu

Pageof 3

Frequent Collaborators

2 joint publications

Stephanie Lheureux

2 joint publications

Amit Oza

2 joint publications

Sarah E Podwika

1 joint publications

Tirza Areli Calderón Boyle